Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants.
OBJECTIVE
Diabetic retinopathy is shown to share many similarities with chronic inflammatory disease, and in diabetes, accelerated apoptosis of retinal capillary cells is evident before histopathology can be seen. The purpose of this study was to examine the effect of interleukin (IL)-1beta on capillary cell apoptosis in rat retina and to determine the effect of antioxidants on diabetes-induced changes in retinal IL-1beta.


METHODS
The effect of injection of IL-1beta into the vitreous (5 ng/5 microL) of normal rats on capillary cell apoptosis (detected by terminal transferase dUTP nick-end labeling [TUNEL]) and formation of acellular capillaries was investigated in the trypsin digested retinal microvessels. The levels of IL-1beta were quantified (by ELISA and Western blot) in the retina of rats diabetic for 2 months, and the effect of administration of antioxidants on diabetes-induced changes in retinal IL-1beta was determined.


RESULTS
The number of TUNEL-positive capillary cells in the retinal microvessels obtained from normal rats that received intravitreal injection of IL-1beta was increased by more than threefold and that of acellular capillaries by more than twofold, compared with the microvessels obtained from rats that received an intravitreal injection of PBS (5 microL) or BSA (5 ng/5 microL). IL-1beta also increased the levels of 8-hydroxy-2'-deoxyguanosine (an indicator of oxidative stress) and nitric oxide by more than 40% and activated NF-kappaB by 35% to 55%. Two months of diabetes in rats increased retinal IL-1beta levels by more than twofold, and antioxidants inhibited such increases.


CONCLUSIONS
IL-1beta, by activation of NF-kappaB and an increase in oxidative stress, plays an important role in the retinal microvascular disease that is characteristic of diabetic retinopathy. Antioxidants inhibit diabetes-induced increases in retinal IL-1beta. These studies offer a possible rationale to test IL-1beta-targeted therapies to inhibit the development of retinopathy in diabetes.
Kowluru
Renu A
RA
Kresge Eye Institute, Wayne State University, Detroit, Michigan 48201, USA. rkowluru@med.wayne.edu
Odenbach
Sarah
S
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D002196:Capillaries; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D003930:Diabetic Retinopathy / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D004797:Enzyme-Linked Immunosorbent Assay; D020287:In Situ Nick-End Labeling; D007375:Interleukin-1 / Q000494:pharmacology / Q000502:physiology*; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D012171:Retinal Vessels / Q000187:drug effects* / Q000473:pathology
D000975:Antioxidants; D007375:Interleukin-1; D016328:NF-kappa B; D009569:Nitric Oxide; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine